Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Georg F. Weber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1175-4505; OpenAlex author ID A5102820098. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers · 2026: 2 papers

Papers 21

  1. Immune Cell-Specific and Isoform-Selective Regulation of CD44 in Pancreatic Ductal Adenocarcinoma Links Lymph Node Variant Loss and Exosomal CD44 to Clinical O… Co-author DOI 10.3390/cells15050411↗
  2. Post-Surgical Remodeling of Circulating Monocytes Identifies CD86 Expression on Non-Classical Monocytes as a Prognostic Indicator in Pancreatic Ductal Adenocar… Co-author DOI 10.3390/ijms27115012↗
  3. Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17091424↗
  4. The Prognostic Role of Para-Aortic Lymph Node Metastasis in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17213418↗
  5. Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarc… Last author DOI 10.3390/ijms26041500↗
  6. Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26072875↗
  7. Identification of Cancer Associated Fibroblasts Related Genes Signature to Facilitate Improved Prediction of Prognosis and Responses to Therapy in Patients wit… Co-author DOI 10.3390/ijms26104876↗
  8. Prognostic role of nutrition parameters on short- and long-term outcome in patients with primary resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clnesp.2024.06.002↗
  9. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients. Co-author DOI 10.1016/j.pan.2024.07.017↗
  10. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma pat… Co-author DOI 10.1038/s41598-024-70916-3↗
  11. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Last author DOI 10.3389/fimmu.2024.1253072↗
  12. Neutrophil-to-Lymphocyte Ratio and Prognostic Nutritional Index Are Predictors for Overall Survival after Primary Pancreatic Resection of Pancreatic Ductal Ade… Co-author DOI 10.3390/cancers16162911↗
  13. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Co-author DOI 10.1186/s13045-023-01404-w↗
  14. Impact of Aspirin Intake on Postoperative Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma-A Single-Center Evaluation. Co-author DOI 10.3390/biomedicines11051466↗
  15. Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. Last author DOI 10.3390/cancers15020363↗
  16. [Better Therapy for Pancreatic Cancer through More Radical Surgery?] Co-author DOI 10.1055/a-1766-7643↗
  17. Impact of Patient Age on Postoperative Short-Term and Long-Term Outcome after Pancreatic Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14163929↗
  18. Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC. Co-author DOI 10.3390/jcm11154433↗
  19. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ducta… Last author DOI 10.3390/ijms21051779↗
  20. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Last author DOI 10.3390/ijms20184543↗
  21. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. Last author DOI 10.1016/j.tranon.2018.03.003↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Grützmann · 19 shared papers, 2018–2026 · strength 3.68
  2. Christian Krautz · 17 shared papers, 2019–2026 · strength 3.35
  3. Maximilian Brunner · 17 shared papers, 2019–2026 · strength 3.35
  4. Anke Mittelstädt · 10 shared papers, 2022–2026 · strength 2.01
  5. Paul David · 8 shared papers, 2023–2026 · strength 1.55
  6. Anne Jacobsen · 7 shared papers, 2020–2026 · strength 1.29
  7. Frederik J. Hansen · 6 shared papers, 2023–2026 · strength 1.08
  8. Isabelle Kuchenreuther · 4 shared papers, 2024–2026 · strength 0.80
  9. Alara Karabiber · 4 shared papers, 2024–2026 · strength 0.79
  10. Danilo Hackner · 4 shared papers, 2022–2024 · strength 0.76
  11. Lisa-Sophie Arnold · 3 shared papers, 2024–2026 · strength 0.58
  12. Christian P. Pilarsky · 4 shared papers, 2018–2025 · strength 0.58
  13. Yong Jian Zhou · 2 shared papers, 2025–2026 · strength 0.46
  14. Sophie Bareiß · 1 shared paper, 2024 · strength 0.26
  15. Axel Denz · 2 shared papers, 2018–2024 · strength 0.24
  16. Yanxi Lu · 1 shared paper, 2025 · strength 0.24
  17. Timur Buniatov · 1 shared paper, 2024 · strength 0.15
  18. Sabine Semrau · 1 shared paper, 2024 · strength 0.15
  19. Yurdagül Zopf · 1 shared paper, 2024 · strength 0.15
  20. Doreen William · 1 shared paper, 2023 · strength 0.13
  21. Susanne Roth · 1 shared paper, 2023 · strength 0.13
  22. Adrian M. Seifert · 1 shared paper, 2023 · strength 0.13
  23. Thilo Hackert · 1 shared paper, 2023 · strength 0.13
  24. Fang Cheng Wong · 1 shared paper, 2023 · strength 0.13
  25. Mathieu Pecqueux · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.